申请人:Pfizer Inc.
公开号:US04410539A1
公开(公告)日:1983-10-18
Heterocyclic thromboxane synthetase inhibitors of the formula ##STR1## wherein R.sup.1, which is attached to the 2-, 3- or 4-position, is hydrogen, halogen, C.sub.1 -C.sub.4 alkyl, hydroxy or C.sub.1 -C.sub.4 alkoxy; Y, which is attached to the 2- or 3-position, is --COOH, --COO(C.sub.1 -C.sub.4 alkyl) or --CONH.sub.2 ; X is O, S, NH, N(C.sub.1 -C.sub.4 alkyl) or N(benzyl); and R, which is attached to the 5-, 6- or 7-position, is a group of the formula ##STR2## or (3- or 4-pyridyl)-Z.sup.2 - wherein Z.sup.1 is --CH.sub.2 --, --CH.sub.2 CH.sub.2 -- or --CH.sub.2 CH.sub.2 O-- and Z.sup.2 is --CH.sub.2 --, --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --CH.sub.2 O-- or --OCH.sub.2 --; and their pharmaceutically acceptable salts; processes for their preparation, and pharmaceutical compositions containing them.
杂环血栓素合成酶抑制剂的化学式为##STR1##其中R.sup.1,连接到2-、3-或4-位置,是氢、卤素、C.sub.1 -C.sub.4烷基、羟基或C.sub.1 -C.sub.4烷氧基;Y,连接到2-或3-位置,是--COOH、--COO(C.sub.1 -C.sub.4烷基)或--CONH.sub.2;X为O、S、NH、N(C.sub.1 -C.sub.4烷基)或N(苄基);R,连接到5-、6-或7-位置,是化学式##STR2##或(3-或4-吡啶基)-Z.sup.2-其中Z.sup.1为--CH.sub.2 --、--CH.sub.2 CH.sub.2 --或--CH.sub.2 CH.sub.2 O--,Z.sup.2为--CH.sub.2 --、--CH.sub.2 CH.sub.2 --、--CH.dbd.CH--、--CH.sub.2 O--或--OCH.sub.2 --;以及它们的药学上可接受的盐;它们的制备方法和含有它们的药物组合物。